Angelica Root

Metadata

Approved Indications

Commission E

• Loss of appetite (Appetitlosigkeit)
• Dyspeptic complaints such as:
  • Mild gastrointestinal spasms (leichte Magen-Darm-Krämpfe)
  • Feelings of fullness (Völlegefühl)
  • Flatulence (Blähungen)

ESCOP

• No ESCOP monograph exists for Angelica archangelica

EMA/HMPC

• Traditional use: Mild spasmodic gastrointestinal complaints including bloating and flatulence
• Traditional use: Temporary loss of appetite
• Classification based on long-standing traditional use (not well-established use)

Agreement/Disagreement Between Bodies

Commission E and EMA are in good agreement on the core indications: loss of appetite and dyspeptic complaints including flatulence, fullness, and mild GI spasms. ESCOP has not issued a monograph. Neither Commission E nor EMA grants well-established use status, reflecting the absence of clinical trial evidence for angelica root as monotherapy. Commission E is slightly broader in specifying “dyspeptic complaints” as a general category.

Conditions Treated

Primary

• Loss of appetite (anorexia, non-psychiatric, e.g., convalescence)
• Functional dyspepsia
• Flatulence
• Feelings of fullness and bloating
• Mild gastrointestinal spasms/cramps

Secondary

• Nervous gastric complaints (traditional)
• Mild biliary complaints (traditional)

Traditional/Historical

• Infectious diseases and plague (historical — angelica was a famous “plague herb” in medieval Europe, hence the name “archangelica”)
• Colds and respiratory infections (folk medicine)
• Rheumatic complaints (external application, folk medicine)
• General tonic and strengthening agent (folk medicine)
• The plant’s association with the Archangel Michael in medieval tradition reflects its high esteem as a protective/healing herb

Mechanism of Action

1. Bitter-Mediated Digestive Stimulation

• Angelica root acts as a bitter aromatic (Amarum aromaticum), combining bitter taste stimulation with aromatic/carminative properties
• Furanocoumarins and bitter principles activate TAS2R bitter taste receptors on the tongue and in gastrointestinal enteroendocrine cells
• Reflex stimulation via vagal pathways increases:
  • Salivary secretion
  • Gastric acid and pepsin production
  • Bile flow (mild choleretic effect)
  • Pancreatic enzyme secretion
• Bitterness value of angelica root: approximately 1,500-3,000 (moderate; lower than gentian or wormwood)

2. Spasmolytic/Carminative (Essential Oil)

• Essential oil (0.35-1.3%) provides spasmolytic activity on gastrointestinal smooth muscle
• Alpha-pinene, beta-phellandrene, limonene: Monoterpenes that relax smooth muscle via calcium channel modulation
• Reduces intestinal spasms and promotes gas expulsion (carminative effect)
• This dual bitter + spasmolytic mechanism distinguishes angelica from pure bitter drugs like gentian

3. Prokinetic

• Essential oil components stimulate gastrointestinal motility
• Promotes gastric emptying and intestinal transit
• This contributes to relief of fullness and bloating

4. Anti-inflammatory

• Coumarins and furanocoumarins demonstrate anti-inflammatory activity in vitro
• Inhibition of prostaglandin synthesis and NF-kB pathways

5. Contribution to Iberogast (STW 5)

• Angelica root is one of nine plant extracts in the fixed combination STW 5 (Iberogast)
• Within STW 5, angelica root contributes primarily spasmolytic and prokinetic properties
• The efficacy demonstrated in Iberogast clinical trials cannot be attributed to angelica root alone, as STW 5 is studied and approved as a fixed combination

Key Active Constituents

• Furanocoumarins: Angelicin, bergapten (5-methoxypsoralen), imperatorin, xanthotoxin (8-methoxypsoralen), isoimperatorin
• Essential oil (0.35-1.3%): Alpha-pinene, beta-phellandrene, alpha-phellandrene, limonene, p-cymene, myrcene, beta-caryophyllene
• Coumarins: Osthole, umbelliferone, umbelliprenin
• Phenolic acids: Chlorogenic acid, caffeic acid, ferulic acid
• Polysaccharides: Fructans (inulin-type)

Clinical Evidence Summary

Monotherapy Clinical Trials

• No randomized, placebo-controlled clinical trials have been identified for angelica root as monotherapy for dyspepsia or appetite loss
• The Commission E and EMA approvals rely on traditional use documentation, pharmacological plausibility, and the established role of bitter aromatic herbs in European phytotherapy
• This represents a significant evidence gap

Evidence from Iberogast (STW 5) Combination

• Angelica root is a component of STW 5 (Iberogast), which has substantial clinical evidence:
  • Multiple RCTs demonstrating efficacy in functional dyspepsia and IBS
  • Meta-analyses supporting benefit for functional gastrointestinal disorders
  • However, the contribution of individual components (including angelica root) cannot be isolated from the combination data
• See the Iberogast (STW 5) monograph for detailed evidence on the combination product

Preclinical/In Vitro Evidence

• Spasmolytic activity of essential oil demonstrated on isolated gastrointestinal smooth muscle preparations
• Bitter receptor activation confirmed in vitro
• Anti-inflammatory activity of furanocoumarin fractions demonstrated
• Prokinetic effects demonstrated in animal models
• Antimicrobial activity of essential oil against selected enteric pathogens

Traditional Use Evidence

• Documented use in European pharmacopoeias since at least the 16th century
• Central to Scandinavian and German herbal medicine traditions
• Traditional ingredient in bitter liqueurs (e.g., Bénédictine, Chartreuse) and digestive formulations
• Used in traditional Nordic medicine for gastric and respiratory complaints

Evidence Assessment

The pharmacological rationale for angelica root as a bitter aromatic digestive stimulant is well-supported by its chemical composition (furanocoumarins, essential oil, bitter principles). The spasmolytic/carminative properties of the essential oil complement the bitter-mediated secretory stimulation, providing a dual mechanism suited to dyspeptic complaints. However, the complete absence of monotherapy clinical trials means that evidence of clinical efficacy rests entirely on traditional use, pharmacological plausibility, and extrapolation from the Iberogast combination data.

European vs US/Anglophone Consensus

Important distinction: Angelica archangelica (European angelica) should not be confused with Angelica sinensis (dong quai/Chinese angelica), which has entirely different indications (gynecological use) and a separate evidence base. The two species are botanically related but pharmacologically and clinically distinct.

Safety Profile

Contraindications

• Hypersensitivity to Angelica archangelica or other Apiaceae/Umbelliferae
• Gastric or duodenal ulcer: Bitter-mediated stimulation of gastric acid is contraindicated in active peptic ulcer disease
• Pregnancy: Contraindicated (traditional emmenagogue concerns; furanocoumarin content)

Drug Interactions

• Photosensitizing furanocoumarins: Furanocoumarins (bergapten, xanthotoxin, imperatorin) are psoralen-type compounds that can cause photosensitization. Concurrent use with other photosensitizing drugs (tetracyclines, fluoroquinolones, sulfonamides, St. John’s wort) may increase risk of phototoxic reactions.
• Anticoagulant medications: Coumarins in angelica root may theoretically potentiate the effects of warfarin and other coumarin-type anticoagulants. Although clinical case reports are limited, caution and INR monitoring are advised with concurrent use.
• Antacids/Proton pump inhibitors: Angelica root’s bitter-mediated gastric acid stimulation may counteract the therapeutic goal of acid-suppressing medications

Side Effects

• Photosensitivity: The most important adverse effect. Furanocoumarin content can cause phototoxic skin reactions (erythema, blistering) upon UV exposure. Patients should avoid prolonged sun exposure or UV treatment during use.
• Gastrointestinal discomfort at higher doses
• Allergic reactions in individuals sensitized to Apiaceae plants (celery-carrot-mugwort-spice syndrome — cross-reactivity possible)
• Generally well tolerated at recommended doses with appropriate UV precautions

Pregnancy/Lactation

• Pregnancy: Contraindicated. Traditional emmenagogue classification; furanocoumarins have potential mutagenic and phototoxic properties. EMA monograph states use is not recommended during pregnancy.
• Lactation: Insufficient data. Not recommended due to furanocoumarin content and lack of safety studies.
• Children: EMA monograph states use is not recommended in children and adolescents under 18 years due to insufficient data.

Botanical Safety Note

Critical identification concern: Angelica archangelica must be carefully distinguished from toxic Apiaceae relatives, particularly Conium maculatum (poison hemlock) and Aethusa cynapium (fool’s parsley), which can cause fatal poisoning. Wild-harvesting is strongly discouraged; only verified cultivated material should be used.

Clinical Dosage

Internal Use

Preparation Notes

• Timing: Always taken 15-30 minutes before meals for optimal bitter-mediated appetite stimulation and digestive secretion
• Hot infusion is standard preparation (unlike gentian, where cold maceration is sometimes preferred)
• Often combined with other digestive herbs: caraway, fennel, peppermint, or gentian
• For flatulence and bloating: Combination with carminative herbs (caraway, fennel) is traditionally preferred

Duration

• Short to medium-term use: 2-4 weeks
• If symptoms persist beyond 2 weeks, medical consultation is recommended (EMA)
• Not intended for long-term continuous use

Sun Protection

• During treatment with angelica root, avoid prolonged sun exposure and sunbathing
• Use sunscreen if outdoor exposure is unavoidable
• This precaution applies to all preparations containing furanocoumarins

Sources

• German Commission E Monograph: Angelicae radix
• EMA/HMPC Community Herbal Monograph on Angelica archangelica L., radix
• EMA/HMPC Assessment Report on Angelica archangelica L., radix
• European Pharmacopoeia: Angelicae radix monograph
• Wichtl M (ed). Herbal Drugs and Phytopharmaceuticals. 3rd ed. Stuttgart: Medpharm; 2004
• Bos R, et al. Analytical aspects of phytotherapeutic angelica roots. J Chromatogr A. 2002;967(1):159-167
• Sigurdsson S, Gudbjarnason S. Inhibition of acetylcholinesterase by extracts and constituents from Angelica archangelica and Geranium sylvaticum. Z Naturforsch C. 2007;62(9-10):689-693
• Arzneipflanzenlexikon: Angelica archangelica (arzneipflanzenlexikon.info)
• Melzer J, et al. Meta-analysis of clinical trials with STW 5 in functional dyspepsia. Aliment Pharmacol Ther. 2004

Connections

• Closely related to Gentian and Wormwood as bitter digestive herbs, though angelica is classified as a bitter aromatic (Amarum aromaticum) rather than a pure bitter (Amarum purum) like gentian
• Carminative/spasmolytic properties overlap with Caraway and Fennel
• Component of Iberogast (STW 5) — the most clinically studied preparation containing angelica root
• Distinguished from Angelica sinensis (dong quai), which has gynecological rather than digestive indications